Eric Dobmeier, J.D.

Eric has more than 20 years of experience in the biotechnology industry as both an executive and board member. Most recently, he was the President and CEO of Chinook Therapeutics, where he led the company through multiple strategic growth initiatives ultimately leading to its acquisition by Novartis in 2023 for up to $3.5 billion. Prior to Chinook, Mr. Dobmeier was President and CEO of Silverback therapeutics, and before that spent 16 years in a series of positions of increasing responsibility at Seattle Genetics, including Chief Operating Officer, during the company’s growth from 60 to 1,200 employees, from a market cap of $150 million to over $8 billion and through its transition to a commercial company with FDA approval and launch of Adcetris, a novel lymphoma drug. During his career, Mr. Dobmeier has been directly involved in raising more than $2 billion in equity capital and led negotiation of corporate alliances with many leading biotechnology and pharmaceutical companies. He is currently a venture partner at Samsara Biocapital and serves as a Board director for Structure Therapeutics and Janux Therapeutics, as well as several private biotechnology companies.